13F reference period
Q2 2026
Security Snapshot
Lantern Pharma Inc. - Common Stock, $0.0001 par value per share (LTRN) Institutional Ownership
CUSIP: 51654W101
13F Institutional Holders and Ownership History from Q2 2020 to Q3 2026
Institutions Reporting
39
Shares (Excl. Options)
2.88M
Full value: 2,882,855 · shares · 30 Jun 2026Price
$4.17
The headline uses the Q2 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended. Newer periods in the history table contain incoming reports and may be incomplete.
Save this security page for your next review
Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Symbol
- LTRN on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 2,882,855
- Total 13F value
- $12,021,606
- Portfolio coverage rank
- 0%
- Share change
- +786,208
- Value change
- +$3,430,019
- Number of holders
- 39
- Shares outstanding
- 15,148,116
- SEC-reported price per share
- $1.01
- Insider filing price
- $1.01
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source
Key facts
- LTRN - Lantern Pharma Inc. - Common Stock, $0.0001 par value per share is tracked under CUSIP 51654W101.
- 39 institutions reported positions in Q2 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 33 to 39 between Q1 2026 and Q2 2026.
- SEC-reported value moved from to
$2.87M
Full value: $2,872,429 · USD · 31 Mar 2026.$12.02M
Full value: $12,021,606 · USD · 30 Jun 2026
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 39 institutions filings for Q2 2026.
Security key
51654W101
13F reference period
Q2 2026
13F holders
39
13D/G owners
3
CIK / CUSIP context first
Open Q2 2026 holders
LTRN full holder history
Lantern Pharma Inc. SEC filings
Lantern Pharma Inc. company facts
Lantern Pharma Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 51654W101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
LTRN
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| SATTERFIELD THOMAS A JR | 7.6% | +50% | $4,065,750 | +$1,688,850 | 975,000 | +71% | Thomas A. Satterfield, Jr. | 30 Jun 2026 |
| Empery Asset Management, LP | 5% | -50% | $763,450 | -$572,327 | 755,891 | -43% | Empery Asset Management, LP | 30 Sep 2026 |
| Bios Equity Partners, LP | 4.5% | -42% | $1,125,471 | -$518,991 | 571,305 | -32% | BIOS ADVISORS GP, LLC | 15 May 2026 |
As of 30 Jun 2026,
39
institutional investors reported holding
shares of
Lantern Pharma Inc. - Common Stock, $0.0001 par value per share (LTRN).
This represents
19%
of the company’s total
outstanding shares.
2.88M
Full value: 2,882,855 · shares · 30 Jun 202615.15M
Full value: 15,148,116 · shares · Stored outstanding share count13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
19%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Empery Asset Management, LP | 5.6% | 842,669 | 4.1% | $3,513,930 | |
| CM Management, LLC | 3.3% | 500,000 | +100% | 1.3% | $2,085,000 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.8% | 425,118 | +28% | 0% | $1,772,742 |
| RENAISSANCE TECHNOLOGIES LLC | 1.9% | 291,039 | +151% | 0% | $1,213,633 |
| BIOS Capital Management, LP | 1.6% | 249,397 | -71% | 2.5% | $1,039,985 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.68% | 102,819 | -7.9% | 0% | $428,852 |
| VANGUARD FIDUCIARY TRUST CO | 0.33% | 49,950 | +0.69% | 0% | $208,292 |
| CITADEL ADVISORS LLC | 0.32% | 47,895 | 0% | $199,722 | |
| Westside Investment Management, Inc. | 0.32% | 47,850 | -4.4% | 0.03% | $199,537 |
| Quadrature Capital Ltd | 0.26% | 39,593 | 0% | $165,103 | |
| NewEdge Advisors, LLC | 0.18% | 27,049 | -1.3% | 0% | $112,796 |
| HORIZON KINETICS ASSET MANAGEMENT LLC | 0.17% | 25,164 | -4.6% | 0% | $104,934 |
| DAVENPORT & Co LLC | 0.16% | 23,814 | 0% | 0% | $99,304 |
| STATE STREET CORP | 0.16% | 23,652 | 0% | 0% | $98,629 |
| BlackRock, Inc. | 0.15% | 22,350 | -51% | 0% | $93,199 |
| Bank of New York Mellon Corp | 0.14% | 21,301 | 0% | 0% | $88,825 |
| NORTHERN TRUST CORP | 0.12% | 17,485 | +12% | 0% | $72,912 |
| XTX Topco Ltd | 0.11% | 17,415 | 0% | $72,621 | |
| DIMENSIONAL FUND ADVISORS LP | 0.11% | 16,725 | -56% | 0% | $69,744 |
| UBS Group AG | 0.11% | 16,632 | +65% | 0% | $69,355 |
| Focus Partners Wealth | 0.1% | 15,432 | 0% | 0% | $64,351 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.09% | 14,073 | 0% | $58,684 | |
| Cetera Investment Advisers | 0.08% | 12,228 | 0% | 0% | $50,991 |
| MARSHALL WACE, LLP | 0.08% | 11,946 | 0% | $49,815 | |
| Farther Finance Advisors, LLC | 0.07% | 10,975 | 0% | $45,766 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
26
Headline period
Q2 2026
Rows shown
1-25 of 26
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q3 | 35,027 | $35,378 | -$2,601 | $1.01 | 5 |
| 2026 Q2 | 2,882,855 | $12,021,606 | +$3,430,019 | $4.17 | 39 |
| 2026 Q1 | 2,096,647 | $2,872,429 | -$333,005 | $1.37 | 33 |
| 2025 Q4 | 2,280,306 | $6,910,016 | -$64,644 | $3.03 | 33 |
| 2025 Q3 | 2,284,349 | $9,928,721 | +$166,361 | $4.35 | 31 |
| 2025 Q2 | 2,241,170 | $7,081,768 | -$615,229 | $3.16 | 34 |
| 2025 Q1 | 2,423,714 | $8,580,099 | -$194,908 | $3.54 | 30 |
| 2024 Q4 | 2,499,825 | $7,996,845 | -$160,960 | $3.19 | 32 |
| 2024 Q3 | 1,335,871 | $4,902,351 | +$118,888 | $3.67 | 31 |
| 2024 Q2 | 1,286,016 | $6,005,302 | +$572,129 | $4.67 | 39 |
| 2024 Q1 | 1,108,429 | $9,753,422 | +$324,907 | $8.80 | 33 |
| 2023 Q4 | 1,155,318 | $4,944,504 | +$6,767 | $4.28 | 29 |
| 2023 Q3 | 1,153,745 | $3,934,035 | -$18,036 | $3.41 | 26 |
| 2023 Q2 | 1,152,036 | $6,497,253 | +$385,814 | $5.64 | 25 |
| 2023 Q1 | 1,083,678 | $5,233,851 | +$124,192 | $4.83 | 21 |
| 2022 Q4 | 893,594 | $5,395,811 | -$1,734,422 | $6.04 | 21 |
| 2022 Q3 | 1,436,757 | $6,840,000 | +$106,232 | $4.78 | 23 |
| 2022 Q2 | 1,417,902 | $8,060,000 | -$230,429 | $5.70 | 25 |
| 2022 Q1 | 1,452,881 | $10,384,000 | -$1,687,241 | $7.14 | 25 |
| 2021 Q4 | 1,658,393 | $13,121,000 | -$563,118 | $7.98 | 31 |
| 2021 Q3 | 1,400,629 | $15,656,000 | +$604,001 | $11.18 | 24 |
| 2021 Q2 | 1,346,716 | $19,660,000 | -$1,578,997 | $14.60 | 19 |
| 2021 Q1 | 1,403,470 | $25,458,000 | +$23,880,194 | $18.14 | 21 |
| 2020 Q4 | 82,988 | $1,597,009 | -$1,643,167 | $19.24 | 10 |
| 2020 Q3 | 160,127 | $3,017,000 | +$710,980 | $18.84 | 11 |